Phase II trials with an antisense oligonucleotide against HSP-27 in CRPC are underway.
以HSP-27为靶点的反义寡核甘酸正处于第二期临床试验中。
Phase II trials: a phase II trial continues to test the safety of the drug, and begins to evaluate how well the new drug works.
二期试验:二期试验继续研究药物的安全性,并开始评估新药作用的效果。
Results from three Phase III drug trials are expected between 2012 and 2013, while results from two Phase II trials of new MDR-TB drugs are expected in 2012.
三个三期药物实验预计在2012年和2013年之间会得出结论,预计在2012年得到两项新的耐多药结核病药物二期实验的结果。
应用推荐